Studie

A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy, ITCC-054/AAML1621

Erkrankungsgruppe:

Leukämien und MDS

Organsystem:

Blut

Stadium:

Therapierefraktär

Standort:

Essen

EudraCT:

2015-002916-34

Prüfplan-Code:

ITCC-054/AAML1621

Phase:

I/II

Prüfsubstanz:

Bosulif, Bosutinib

Sponsor:

Erasmus MC